Table 3.
Stroke Characteristics Among Participants within the Stroke Groups
| Characteristica | Cancer-Plus-Stroke (n=50) |
Stroke-Only (n=50) |
|---|---|---|
| Stroke Prevention Medicines Before Stroke | ||
| Antiplatelet | 15 (30) | 20 (40) |
| Anticoagulant | 23 (46) | 4 (8) |
| Statin | 18 (36) | 22 (44) |
| Stroke Severity/Functional Status | ||
| NIH stroke scale (IQR) | 3 (2–6) | 2 (0–3) |
| Modified Rankin Scale score (IQR) | 3 (2–4) | 2 (1–4) |
| Radiographic Infarct Pattern | ||
| Involves ≥2 vascular territories | 30 (60) | 5 (10) |
| Involves 3 vascular territories | 22 (44) | 2 (4) |
| Stroke Mechanism b | ||
| Cardioembolic | 18 (36) | 8 (16) |
| Large artery atherosclerosis | 5 (10) | 6 (12) |
| Small vessel disease | 0 (0) | 11 (22) |
| Other determined | 3 (6) | 4 (8) |
| Undetermined | 24 (48) | 21 (42) |
Abbreviations: NIH, National Institutes of Health; IQR, interquartile range.
a
Data reported as number (%) unless otherwise specified.
b
According to the Trial of Org 10172 Acute Stroke Treatment (TOAST) criteria.